Tang GHL, et al. - Using the STS/ACC TVT Registry, researchers analyzed patients who underwent commercial transcatheter aortic valve implantation, to compare those receiving a 31-mm CoreValve to those receiving a 34-mm Evolut R valve for symptomatic severe native aortic stenosis. Following propensity score matching, 1813 patient sets were left for study. Males constituted >92% of the study sample. Most patients were elderly (∼80 years) with an STS score of 6.6%. Higher device success, reduced hospital stay, lower pacemaker rates and less ≥moderate aortic regurgitation were observed in relation to the use of the 34-mm Evolut R valve vs the 31-mm CoreValve bioprosthesis in this largest experience with the 34-mm Evolut R valve.